Chao Lu

Dr. Chao Lu

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
CLChao Lu
Chao Lu
PQPengyun Qiao
Pengyun Qiao
YSYonghong Sun
Yonghong Sun
CRChune Ren
Chune Ren
ZYzhenhai yu
zhenhai yu
Background: Breast cancer (BC) is one of the most common female malignancies in the world. Chemotherapeutic resistance is the major cause of BC therapy failure, leading to tumor recurrence and metastasis. Studies have illustrated the close relationship between glycolysis and BC progression and drug resistance. The key glycolysis regulator, PFKFB3 makes a difference during BC progression and drug resistance. However, the mechanism remains to be unknown.Methods: Mass spectrometry analyses were used to found that PIM2 was a potential new binding protein of PFKFB3. Co‐immunoprecipitated and western blot were used to verify the interaction between PIM2 and PFKFB3 in BC and the molecular mechanism by which PIM2 phosphorylates PFKFB3 in regulating the protein function. PFKFB3 mutant forms were used to demonstrate the need for PFKFB3 in BC drug resistance.Results: We identified that PIM2 is a new binding protein of PFKFB3. We used biochemical methods to determine that PIM2 can directly bind and change the phosphorylation of PFKFB3 at Ser478 to enhance PFKFB3 protein stability through the ubiquitin‐proteasome pathway. Importantly, phosphorylation of PFKFB3 at Ser478 promoted glycolysis, BC cell growth, and paclitaxel resistance together with PIM2 in vitro and in vivo.Conclusion: Our study demonstrates that PIM2 mediates PFKFB3 phosphorylation thus regulates glycolysis and paclitaxel resistance to promote tumor progression in BC and provides preclinical evidence for targeting PFKFB3 as a new strategy in BC treatment to battle paclitaxel resistance.

15 September 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
CLChao Lu
Chao Lu
PQPengyun Qiao
Pengyun Qiao
RFRuihai Fu
Ruihai Fu
YWYadi Wang
Yadi Wang
JLJiayi Lu
Jiayi Lu
ZYzhenhai yu
zhenhai yu
Endometriosis (EM) is one of the vanquished wonted causes of chronic pelvic sting in women and is closely associated with infertility. The long-term, complex, systemic, and post-treatment recurrence of EM wreaks havoc on women’s quality of life. Extensive metabolic reprogramming (aerobic glycolysis, glucose overweening intake, and high lactate production) and cancer-like changes have been found in EM, which bears striking similarities to tumorigenesis. The key glycolysis regulator PFKFB4 is overexpressed in EM. However, the mechanism of PFKFB4 in EM remains unknown. We found that PFKFB4 was upregulated and was closely related to the progression of EM. We identified focus PIM2 as a new pioneering adjoin protein of PFKFB4. Vigorous biochemical methods were used to confirm that PIM2 phosphorylated site Thr140 of PFKFB4. PIM2 also could enhance PFKFB4 protein expression through the ubiquitin–proteasome pathway. Moreover, PIM2 expression was really corresponding prevalent with PFKFB4 in endometriosis in vivo. Importantly, phosphorylation of PFKFB4 on Thr140 by PIM2 promoted EM glycolysis and cell growth. Our study demonstrates that PIM2 mediates PFKFB4 Thr140 phosphorylation thus regulating glycolysis and EM progression. We illustrated a new mechanism that PIM2 simulated a central upstream partnership in the regulation of PFKFB4, and reveal a novel means of PIM2-PFKFB4 setting EM growth. Our research provided new theoretical support for further clarifying the reprogramming of EM glucose metabolism, and provided new clues for exploring non-contraceptive treatments for EM.

1 May 2020 in Molecular Cancer Research
Verified
Journal Article
Open access
PDF file
CLChao Lu
Chao Lu
CRChune Ren
Chune Ren
TYTingting Yang
Tingting Yang
YSYonghong Sun
Yonghong Sun
PQPengyun Qiao
Pengyun Qiao
ZYzhenhai yu
zhenhai yu
Breast cancer is a leading cause of death in women worldwide, but the underlying mechanisms of breast tumorigenesis remain unclear. Fructose-1, 6-bisphosphatase 1 (FBP1), a rate-limiting enzyme in gluconeogenesis, was recently shown to be a tumor suppressor in breast cancer. However, the mechanisms of FBP1 as a tumor suppressor in breast cancer remain to be explored. Here we showed that FBP1 bound to Notch1 in breast cancer cells. Moreover, FBP1 enhanced ubiquitination of Notch1, further leading to proteasomal degradation via FBXW7 pathway. In addition, we found that FBP1 significantly repressed the transactivation of Notch1 in breast cancer cells. Functionally, Notch1 was involved in FBP1-mediated tumorigenesis of breast cancer cells in vivo and in vitro. Totally, these findings indicate that FBP1 inhibits breast tumorigenesis by regulating Notch1 pathway, highlighting FBP1 as a potential therapeutic target for breast cancer. Implications: We demonstrate FBP1 as a novel regulator for Notch1 in breast cancer.

14 October 2022 in iScience
Verified
Journal Article
Open access
XLXi Ling
Xi Ling
JLJiayi Lu
Jiayi Lu
XWXiaoyun Wang
Xiaoyun Wang
LLLan Liu
Lan Liu
LLLu Liu
Lu Liu
ZYzhenhai yu
zhenhai yu
Endometriosis is a common chronic condition characterized by abnormal growth of the endometrium outside the uterus. Heat shock transcription factor 1 (HSF1) is a significant regulator of the proteotoxic stress response and plays an essential role in developing endometriosis. However, the mechanisms regulating HSF1 protein stability in endometriosis remain unclear. Here, we demonstrate that OTUB1 interacts with HSF1 and promotes HSF1 protein stability through deubiquitination. In addition, OTUB1 enhances glycolysis and epithelial-mesenchymal transition of endometriosis cells, leading to promote proliferation, migration, and invasion of endometriosis cells. The progression of endometriosis is inhibited in an OTUB1-knockout mouse model. In summary, OTUB1 promotes the development of endometriosis by up-regulating HSF1. OTUB1/HSF1 axis may become a new therapeutic target for endometriosis.

1 November 2018 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Closed access
CZChangwen Zhang
Changwen Zhang
CLChao Lu
Chao Lu
ZWZHEN WANG
ZHEN WANG
GFGuowei Feng
Guowei Feng
EDE. Du
E. Du
ZZZhihong Zhang
Zhihong Zhang

19 January 2024 in Journal of Affective Disorders
Verified
Journal Article
Closed access
YWYadi Wang
Yadi Wang
RWRan Wei
Ran Wei
ZCZhenna Chen
Zhenna Chen
YTYujie Tang
Yujie Tang
LLLu Liu
Lu Liu
CLChao Lu
Chao Lu